CORvalenTM (D-Ribose) Improves Pain And Quality Of Life In Fibromyalgia And Chronic Fatigue Patients
That's what Jacob Teitelbaum, MD, and Valen Labs wanted to determine with an open label, 41-patient feasibility study, the results of which are now being released.
The study had two endpoints: assessing the level of relief in symptoms of fatigue and pain; and determining changes in patient quality of life.
The patients in the study had an average age of 48 years and were 78-percent female, which is in keeping with the general population as fibromyalgia and chronic fatigue syndrome affect twice as many women as men and typically first appears at middle age.
At the start of the study the patients completed a 10-point quality of life visual analog scale and then took five grams of CORvalenTM D-ribose orally, three times a day, for an average of 28 days.
After the 28-day treatment period the QOL questionnaire was repeated, and 69-percent of the 36 patients who completed the course of CORvalenTM treatment had significant improvement in their symptoms. They also averaged a 25-percent improvement in the QOL scale.
"What this did was verify what we already knew about the impact of ribose on energy recovery in muscles generally," says Jacob Teitelbaum, MD, Medical Director of the Center for Effective CFS/Fibromyalgia Therapies in Annapolis, Maryland. "But specifically we determined the energy building benefit of ribose directly improved the debilitating symptoms of these conditions. I think this study, and follow on studies now in development, will make ribose one of the most important new nutrients studies in the next few years."
Any bit of good news on the relief front - from ribose or otherwise - will certainly be welcome by the over two million Americans who suffer from widespread pain, sleep disturbances, fatigue, reduced exercise tolerance, irritable bowel syndrome, anxiety, depression, headaches and other symptoms of fibromyalgia and chronic fatigue syndrome.
"Despite the fact chronic pain syndrome with fibromyalgia-like symptoms have been described in medical literature for over 200 years, we still don't know the exact cause," states Clarence Johnson, CEO of Bioenergy and Valen Labs. "We do know however that people with fibromyalgia have lower levels of the energy molecule called adenosine triphosphate (ATP) and a reduced capacity to make ATP in their muscles. We know from previous studies ribose can fuel ATP synthesis and are gratified to see this latest piece of science showing ribose supplementation can reduce muscle pain and enhance quality of life for those suffering with fibromyalgia and/or chronic fatigue."
Bioenergy, Inc., is a privately-held, Minneapolis-based life sciences company whose core technology lies in the development and commercialization of products based on the physiological benefits of D-ribose in health and wellness. Bioenergy's clear mission is to develop products that increase the quality of its customers' lives by improving the function of their hearts, muscles, and other body tissues. Valen Labs, Inc., its subsidiary, markets ribose-based products to the functional food and clinical nutrition markets. Valen's products include Bioenergy RIBOSETM, a functional ingredient in the active lifestyle market; CORvalenTM, a clinical nutrition product giving metabolic support to heart patients; and CORvalenMTM, a dietary supplement that helps relieve myalgia, muscle soreness, cramping and fatigue.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Nordqvist, Christian. "CORvalenTM (D-Ribose) Improves Pain And Quality Of Life In Fibromyalgia And Chronic Fatigue Patients." Medical News Today. MediLexicon, Intl., 9 Feb. 2006. Web.
23 Jun. 2017. <http://www.medicalnewstoday.com/releases/37399.php>
Nordqvist, C. (2006, February 9). "CORvalenTM (D-Ribose) Improves Pain And Quality Of Life In Fibromyalgia And Chronic Fatigue Patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.